PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
48.96%
Some net income increase while TRVN is negative at -87.63%. John Neff would see a short-term edge over the struggling competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.88%
Less SBC growth vs. TRVN's 141.54%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-128.88%
Negative yoy working capital usage while TRVN is 265.47%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-244.33%
Negative yoy AP while TRVN is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
1043.06%
Growth well above TRVN's 265.47%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-114.48%
Negative yoy while TRVN is 774.62%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-59.54%
Both yoy CFO lines are negative, with TRVN at -57.85%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.03%
Debt repayment well below TRVN's 100.00%. Michael Burry suspects heavier leverage risk or insufficient cash generation to keep pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.